Φορτώνει......
Cost Effectiveness Analysis of Direct Oral Anticoagulant (DOAC) versus Dalteparin for the Treatment of Cancer Associated Thrombosis (CAT) in the United States
INTRODUCTION: While trials have demonstrated non-inferiority of direct oral anticoagulant drugs (DOAC) to low-molecular-weight heparins (LMWH) for the treatment of cancer associated thrombosis (CAT), it is unclear if the newer intervention is cost-effective. METHODS: We performed a cost-utility anal...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Thromb Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6661186/ https://ncbi.nlm.nih.gov/pubmed/31200341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.thromres.2019.05.012 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|